Bristol Myers Squibb Reports Preliminary Phase 3 KarXT Data in Alzheimer's Psychosis
Bristol Myers Squibb on Wednesday released preliminary Phase 3 results from two studies in its ADEPT program testing KarXT in psychosis associated with Alzheimer's disease. According to the company, both short- and long-term treatment with the drug reduced hallucinations and delusions in patients.
The readout is the first clinical data presented from the ADEPT program, which evaluates KarXT — the company's schizophrenia drug — in patients experiencing Alzheimer's-related psychosis. The company described the findings as preliminary.
The initial announcements did not include detailed efficacy statistics from the two trials. Bristol Myers Squibb reported revenue of 48.20 billion USD in fiscal 2025.